Research in mice and non-human primates has demonstrated that costimulation-blockade resistant organ rejection following transplantation is primarily mediated by donor-reactive CD8+ T cells. Controlling these alloreactive T cell responses is imperative for improving long-term outcomes in pediatric and adult transplant recipients. The Ig-superfamily member 2B4 (SLAMf4, CD244) has been shown to be inducibly expressed on ??-CD8+ T cells. Our recent studies suggest that 2B4 plays a functional role in the inhibition of donor-reactive CD8+ T cell responses following CD28 costimulation blockade in vivo, raising the possibility that 2B4 itself could be a therapeutic target to attenuate allograft rejection. Preliminary data suggest that 2B4 may function as a costimulator during primary pathogen- specific CD8+ T cell activation and raise the exciting possibility that 2B4 could be specifically manipulated to attenuate acute graft rejection mediated by alloreactive CD8+ T cells following transplantation, while simultaneously maintaining functional immune responses capable of defending the host from pathogen infections. This work will test the concept that graft-specific and pathogen-specific CD8+ T cells express different complements of costimulatory and coinhibitory molecules. We propose that certain signaling pathways in T cells may be differentially engaged in the setting of infection and transplant and that these responses can be exploited to maximize protective immunity and minimize the risk of rejection following transplantation.

Public Health Relevance

The proposed research is relevant to public health because it characterizes expression and function of a cosignaling molecule that could be manipulated to attenuate alloreactive T cell responses following transplantation while maintaining protective immune responses against foreign pathogens. This contribution is relevant to NIH's mission in that it may facilitate the development of safe and effective immunosuppression for patients receiving solid organ transplants for the treatment of chronic liver, kidney, and lung diseases among others.

National Institute of Health (NIH)
Predoctoral Individual National Research Service Award (F31)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Adger-Johnson, Diane S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
Schools of Medicine
United States
Zip Code